Hainan Haiyao: First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

Hainan Haiyao (000566.SZ): The Phase III clinical trial for Fufeninone capsules, a Class 1 new drug for anti-hepatic fibrosis, is now in accelerated preparation.

On April 16, Hainan Haiyao (000566.SZ) announced on the investor interaction platform that the Phase III clinical trial for its anti-hepatic fibrosis Class 1 new drug, Fluorofenidone Capsules, is being expedited. The company will fulfill its information disclosure obligations in a timely manner based on progress updates. Investors are advised to be mindful of investment risks.

Gelonghui FinanceApr 16 22:13

Hainan Haiyao: 2025 Annual Report

SZSIApr 11 00:00 · Announcements

Hainan Haiyao: Summary of the 2025 Annual Report

SZSIApr 11 00:00 · Announcements

Express News | Hainan Haiyao: Plans to Reduce Stake in China Antibody by Up to 5%

BreakingsApr 3 20:44

Hainan Haiyao (000566.SZ): Currently, there is no BD plan for the flunarizine capsule.

Hainan Haiyao (000566.SZ) stated on the investor interaction platform that Fluorofenidone capsules are targeted at liver fibrosis caused by the hepatitis B virus. Given that the patient population for this disease is primarily within the domestic market, there are currently no business development (BD) plans for Fluorofenidone capsules.

Gelonghui FinanceMar 24 23:59